James Winkler

James Winkler

Company: OnKure Inc.

Job title: Vice President - Biology & Translational Medicine


OKI-179, an Oral Class 1-selective Depsipeptide HDAC Inhibitor: Phase 1 Results & Phase 2 Plans 1:00 pm

OKI-179 is an oral depsipeptide HDAC Class 1 inhibitor, the same class as the IV drug romidepsin Demonstrating how OKI-179 has completed Phase 1 with excellent PK, PD and safety Discussing a molecular approach to Phase 2 trialsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.